The life sciences team at Birmingham-based law firm Gowling WLG has advised on a trio key projects relating to potential COVID-19 vaccines.
Want to share your news with your industry? Submit a press release.
Top 1000 Companies Ranked by Revenue – in Multiple Sectors & Countries.
The first was advising AstraZeneca on its collaboration agreement for the development and distribution of the University of Oxford’s recombinant adenovirus vaccine.
The team also advised BioNTech on IP matters relating to the Pfizer/BioNTech COVID-19 vaccine.
The Canadian arm of the firm advised Precision NanoSystems, Inc (PNI) on its agreement with Can Sino Biologics Inc. to co-develop an mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19.
Patrick Duxbury, head of life sciences (UK), said: “We are hugely proud to have supported our clients in these projects including in relation to two COVID-19 vaccines which have now been approved. Delivering on these projects is the result of a huge team effort to support the global response to COVID-19. We drew on our international and sector expertise to help our clients move forward swiftly and to navigate the complex legal considerations involved.”
The trio of projects are the latest in a number of pieces of COVID-19 related advice provided by Gowling WLG. Teams across the firm have been assisting clients in their response to COVID-19, for example, the firm’s commercial contracts specialists provided advice on a consortium agreement for the manufacture of ventilators for the NHS.
Its real estate team also advised Warwickshire County Cricket Club on developing the stadium to create a drive-through COVID-19 testing station for regularly testing NHS staff.